“Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial”, J of Skin, vol. 7, no. 2, p. s196, Mar. 2023, doi: 10.25251/skin.7.supp.196.